RxDoctor Payments Data

Thomas Sneeringer, DO

Family Medicine · Brookville, PANPI 1366431553

Payments from drug & device makers

$13,998in general payments, 2019–2025

Across 969 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • AbbVie$1K
  • Amgen$949
  • Johnson & Johnson$631
  • plus $7K from 47 others

What the payments were for

  • Food & beverage$13,963100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,998 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$157,676
Medicare patients
403
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol170$133,942
EliquisApixaban96$95,969
JardianceEmpagliflozin93$88,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,537
MounjaroTirzepatide21$24,245
OzempicSemaglutide26$23,546
TrulicityDulaglutide26$23,000
RybelsusSemaglutide17$19,528
EntrestoSacubitril/Valsartan21$16,813
Repatha SureclickEvolocumab24$13,576
MyrbetriqMirabegron23$9,656
Xtampza ErOxycodone Myristate12$7,741
Repatha SyringeEvolocumab14$7,228
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen283$5,690
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro16$5,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,564$133,942170 claims
PfizerEliquis$1,421$95,96996 claims
Boehringer IngelheimJardiance$598$88,23193 claims
Lilly USA, LLCMounjaro, Trulicity$442$47,24547 claims
Novo NordiskOzempic, Rybelsus$1,530$43,07443 claims
GSKTrelegy Ellipta, Breo Ellipta$612$29,92753 claims
NovartisEntresto$261$16,81321 claims
Astellas Pharma US IncMyrbetriq$303$9,65623 claims
AbbVieLumigan$1,392$5,21318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Brookville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →